Literature DB >> 26992946

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC).

Jean El Cheikh1, Patrick Sfumato2, Mohamad Sobh3, Nathalie Fegueux4, Mohamad Mohty5, Stephane Vigouroux6, Yves Beguin7, Ibrahim Yakoub-Agha8, Gerard Socié9, Jerome Cornillon10, Melanie Mercier11, Jacques Olivier Bay12, Didier Blaise13, Mauricette Michallet3, Regis Peffault de Latour9.   

Abstract

Entities:  

Keywords:  allogeneic stem cell transplantation; elderly patients; unrelated donors

Mesh：

Year:  2016        PMID： 26992946      PMCID： PMC5013964          DOI： 10.3324/haematol.2015.139345

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

2.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.

Authors:  Didier Blaise; Raynier Devillier; Anne-Gaëlle Lecoroller-Sorriano; Jean-Marie Boher; Agnès Boyer-Chammard; Reza Tabrizi; Patrice Chevallier; Nathalie Fegueux; Anne Sirvent; Mauricette Michallet; Jacques-Olivier Bay; Sabine Fürst; Jean El-Cheikh; Laure Vincent; Thierry Guillaume; Caroline Regny; Noël Milpied; Luca Castagna; Mohamad Mohty
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

4.  Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

Authors:  Patrice Chevallier; Richard M Szydlo; Didier Blaise; Reza Tabrizi; Mauricette Michallet; Madalina Uzunov; Nathalie Fegueux; François Guilhot; Simona Lapusan; Nicole Gratecos; Jean-Yves Cahn; Gerard Socié; Ibrahim Yakoub-Agha; Anne Huynh; Sylvie Francois; Jacques-Olivier Bay; Sébastien Maury; Agnes Buzyn; Nathalie Contentin; Mohamad Mohty
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-23       Impact factor: 5.742

5.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

6.  A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.

Authors:  Raynier Devillier; Sabine Fürst; Roberto Crocchiolo; Jean El-Cheikh; Luca Castagna; Samia Harbi; Angela Granata; Evelyne D'Incan; Diane Coso; Christian Chabannon; Christophe Picard; Anne Etienne; Boris Calmels; Jean-Marc Schiano; Claude Lemarie; Anne-Marie Stoppa; Reda Bouabdallah; Norbert Vey; Didier Blaise
Journal:  Am J Hematol       Date:  2014-01       Impact factor: 10.047

7.  Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.

Authors:  John Koreth; Julie Aldridge; Haesook T Kim; Edwin P Alyea; Corey Cutler; Philippe Armand; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Vincent T Ho
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-13       Impact factor: 5.742

8.  Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.

Authors:  Mohamad Mohty; Florent Malard; Didier Blaise; Noel Milpied; Sabine Furst; Resa Tabrizi; Thierry Guillaume; Stéphane Vigouroux; Jean El-Cheikh; Jacques Delaunay; Steven Le Gouill; Philippe Moreau; Myriam Labopin; Patrice Chevallier
Journal:  Cancer       Date:  2014-10-03       Impact factor: 6.860

9.  Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Authors:  Yi-Bin Chen; Erin Coughlin; Kevin F Kennedy; Edwin P Alyea; Philippe Armand; Eyal C Attar; Karen K Ballen; Corey Cutler; Bimalangshu R Dey; John Koreth; Steven L McAfee; Thomas R Spitzer; Joseph H Antin; Robert J Soiffer; Vincent T Ho
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-02       Impact factor: 5.742
  9 in total
  2 in total

1.  Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.

Authors:  Fiona He; Qing Cao; Aleksandr Lazaryan; Claudio Brunstein; Shernan Holtan; Erica Warlick; Celalettin Ustun; Brian McClune; Mukta Arora; Armin Rashidi; Craig Eckfeldt; Daniel J Weisdorf; Nelli Bejanyan
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-15       Impact factor: 5.742

Review 2.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.